The National Hemophilia Foundation (NHF) Central Ohio Chapter is dedicated to finding cures for inheritable blood disorders and addressing and preventing the complications of these disorders through research, education, and advocacy enabling people and families to thrive.
Our Mission ... In Action
News & Announcements
NHF is very pleased to announce that the Kevin Child Scholarship (KCS) application deadline has been set for August 2, 2021! The scholarship is named in tribute to Kevin Child, who died of AIDS in 1989, shortly before graduating from college. It is awarded annually to a student with hemophilia who is about to enter or currently enrolled in a program of higher education.
Shared decision making (SDM), the concept by which patients and healthcare providers work closely together to arrive at personalized treatment-related decisions, can have significant positive impacts for individuals with hemophilia.
A new paper published in The Journal of Haemophilia Practice advances the concept of shared decision making (SDM) between the hemophilia patient and their healthcare provider (HCP).
A new article, “Emerging Immunogenicity and Genotoxicity Considerations of Adeno-Associated Virus Vector Gene Therapy for Hemophilia,” was published in the Journal of Clinical Medicine (JCM).
In this review, the authors discuss some of the primary considerations relevant to investigational gene therapies that employ adeno-associated viral (AAV) vectors, with particular focus on immunogenicity and genotoxicity – the former denotes the ability of a foreign substance to trigger an immune response, while the latter refers to a substances ability to damage genetic material.